Please log in to determine if you are eligible to purchase PT Programs.
HLA DRUG HYPERSENSITIVITY - PGX2
PGX2
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Analyte/Procedure Challenges per Shipment Number of Shipments
HLA‑B*15:02 3 Two shipments per year
HLA‑B*57:01 3

Additional Information

  • Designed for laboratories that provide HLA‑B*57:01 testing to identify risk of hypersensitivity to abacavir and HLA-B*15:02 testing to identify risk of hypersensitivity to carbamazepine. The intended response is qualitative (presence/absence of the allele). This Survey is not appropriate for laboratories that perform molecular HLA typing. For HLA typing proficiency testing, please consult the HLA Molecular Typing (DML) Survey.

Program Information

  • Three 25.0‑μg extracted DNA specimens
  • Includes allele detection (genotyping) and/or interpretive challenges

Shipping Schedule

  • Shipment A: April 20
  • Shipment B: September 14






Customers Who Bought This Item Also Bought
HLA DISEASE ASSOCIATION-DRUG RISK
VIEW DETAILS >
CLASS I & II HLA MOLECULAR TYPING
VIEW DETAILS >